Physician profile
Dragos Vasile
NPI 1063496743
$1,142.94
in general payments reported to CMS, 2019-2025
13 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.86 · 2022: $137 · 2023: $428 · 2024: $238 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $295.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $165.83 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $140.55 | 2022-2024 | Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.29 | 2019-2023 | Jardiance |
| Abbvie INC. | $120.49 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $79.52 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $78.12 | 2019-2025 | Trelegy Ellipta |
| Lundbeck LLC | $41.62 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $28.89 | 2024 | |
| Novo Nordisk INC | $22.58 | 2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $17.22 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $16.77 | 2025 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dragos Vasile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.